Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 20/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 10/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 10/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8358373 | 1.00 | ITGAL (0.44) | ITGALITGB2ICAM1 | |
| SCHEMBL4850591 | 0.91 | ITGAL (0.37) | ITGALITGB2ICAM1 | |
| SCHEMBL14040877 | 0.89 | IDH1 (0.37) | ITGALITGB2ICAM1 | |
| SCHEMBL14040721 | 0.88 | ITGAL (0.46) | ITGALITGB2ICAM1 | |
| SCHEMBL14040688 | 0.88 | ITGAL (0.44) | ITGALITGB2ICAM1 | |
| SCHEMBL8354466 | 0.88 | ITGAL (0.44) | ITGALITGB2ICAM1 | |
| SCHEMBL4864222 | 0.88 | ITGAL (0.44) | ITGALITGB2ICAM1 | |
| SCHEMBL4840120 | 0.86 | ITGAL (0.52) | ITGALITGB2ICAM1 | |
| SCHEMBL4849061 | 0.86 | ITGAL (0.52) | ITGALITGB2ICAM1 | |
| SCHEMBL4847894 | 0.86 | ITGAL (0.52) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472257-B1 | INHIBITORS OF ALPHA L BETA 2 INTEGRIN MEDIATED CELL ADHESION | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-7375128-B2 | Inhibitors of α1 β2 integrin mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375128-B2 | Inhibitors of α1 β2 integrin mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7199125-B2 | Spiro-cyclic compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199125-B2 | Spiro-cyclic compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050171174-A1 | Inhibitors of alpha l beta 2 integrin mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-08-04 | — | — | US | disclosed |
| WO-2003066636-A1 | INHIBITORS OF ALPHA L BETA 2 INTEGRIN MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171174-A1 | Inhibitors of alpha l beta 2 integrin mediated cell adhesion | ITGB1, ITGB2, ITGA2 | ITGAL 5/4885ITGB2 2/4885ICAM1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.